Farouque H M Omar, Worthley Stephen G, Meredith Ian T
Cardiovascular Research Centre, Monash Medical Centre and Monash University, Melbourne, Australia.
Arterioscler Thromb Vasc Biol. 2004 May;24(5):905-10. doi: 10.1161/01.ATV.0000125701.18648.48. Epub 2004 Mar 11.
Experimental evidence indicates that ATP-sensitive potassium (K(ATP)) channels regulate coronary blood flow (CBF). However, their contribution to human coronary metabolic vasodilation is unknown.
Seventeen patients (12 male, age 58+/-10 years) were studied. Coronary hemodynamics were assessed before and after K(ATP) channel inhibition with subselective intracoronary glibenclamide infused at 40 microg/min in an angiographically smooth coronary artery after successful percutaneous coronary intervention to another vessel. Metabolic vasodilation was induced by 2 minutes of rapid right ventricular pacing. Coronary blood velocity was measured with a Doppler guidewire and CBF calculated. The time course of hyperemia was recorded for 2 minutes after pacing, and hyperemic volume was estimated from the area under the flow-versus-time curve (AUC). Compared with vehicle infusion (0.9% saline), glibenclamide reduced resting CBF by 9% (P=0.04) and increased resting coronary vascular resistance (CVR) by 15% (P=0.03). Glibenclamide reduced pacing-induced peak CBF (50.8+/-6.8 versus 42.0+/-5.4 mL/min, P=0.001), peak CBF corrected for baseline flow (25.1+/-4.6 versus 17.6+/-3.1 mL/min, P=0.01), and increased minimum CVR (2.6+/-0.3 versus 3.1+/-0.3 mm Hg/mL per minute, P=0.002). Compared with vehicle, glibenclamide reduced total AUC at 2 minutes (3535+/-397 versus 3027+/-326 mL, P=0.001).
Vascular K(ATP) channels appear to be involved in functional coronary hyperemia after metabolic stimulation.
实验证据表明,三磷酸腺苷敏感性钾(K(ATP))通道调节冠状动脉血流量(CBF)。然而,它们对人体冠状动脉代谢性血管舒张的作用尚不清楚。
对17例患者(12例男性,年龄58±10岁)进行了研究。在成功对另一血管进行经皮冠状动脉介入治疗后,于血管造影显示光滑的冠状动脉内以40微克/分钟的速度注入亚选择性冠状动脉内格列本脲,抑制K(ATP)通道前后评估冠状动脉血流动力学。通过快速右心室起搏2分钟诱导代谢性血管舒张。用多普勒导丝测量冠状动脉血流速度并计算CBF。起搏后记录2分钟的充血时间过程,并根据流量-时间曲线下面积(AUC)估算充血量。与注入载体(0.9%盐水)相比,格列本脲使静息CBF降低9%(P=0.04),使静息冠状动脉血管阻力(CVR)增加15%(P=0.03)。格列本脲降低了起搏诱导的峰值CBF(50.8±6.8对42.0±5.4毫升/分钟,P=0.001)、校正基线流量后的峰值CBF(25.1±4.6对17.6±3.1毫升/分钟,P=0.01),并增加了最小CVR(2.6±0.3对3.1±0.3毫米汞柱/毫升每分钟,P=0.002)。与载体相比,格列本脲使2分钟时的总AUC降低(3535±397对3027±326毫升,P=0.001)。
血管K(ATP)通道似乎参与代谢刺激后的功能性冠状动脉充血。